References
- 1. Copland M. Chronic myelogenous leukemia stem cells: What's new? Curr Hematol Malig Rep. 2009;4(2):66-73.
- 2. Deininger M, Goldman J, Melo J. The molecular biology of chronic myeloid leukemia. Blood. 2000;96:3343-3356.
- 3. Serpa M, Sanabani SS, Dorliac-Llacer PE, Conchon M. Molecular measurement of BCR-ABL transcript variations in chronic myeloid leukemia patients in cytogenetic remission. BMC Blood Disorders. 2010;10:7.
- 4. Pavlu J, Richard MSz, Goldman JM, Apperley JF. Three decades of transplantation for chronic myeloid leukemia: what have we learned? Blood. 2011;117:755-763.
- 5. Belli C, Alú MF, Alfonso G, Bianchini M, Larripa I. Novel variant Ph translocation t(9;22;11)(q34;q11.2;p15)inv(9)(p13q34) in chronic myeloid leukemia involving a one-step mechanism. Cytogenet Genome Res. 2011;132(4):304-8. Epub 2011 Jan 6.
- 6. Jabbour E, Cortes J, Kantarjian H. Optimal First-Line Treatment of Chronic Myeloid Leukemia: How to Use Imatinib and What Role for Newer Drugs? Oncology. 2007;21(6):653-62.
- 7. Litzow MR. Imatinib resistance: obstacles and opportunities. Arch Pathol Lab Med. 2006;130:669-679.
- 8. Deininger MW. Milestones and Monitoring in Patients with CMLTreated with Imatinib. ASH Education Book. 2008;1:419-426.
- 9. Hughes T, Deininger M, Hochhaus A, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood. 2006;108(1):28-37.
- 10. Provan D, Singer RJ, Baglin T, Dokal I. Oxford Handbook of Clinical Hematology, Oxford University Press, third edition, Oxford, 2009, pg. 140-147.
- 11. Kantarjian HM, Shan J, Jones D, et al. Significance of Increasing Levels of Minimal Residual Disease in Patients With Philadelphia Chromosome- Positive Chronic Myelogenous Leukemia in Complete Cytogenetic Response J Clin Oncol. 2009;27(22):3659-3663.